David Weingeist
Scientific Director, Oncology Precision Medicine & Diagnostics Johnson & Johnson
Seminars
Wednesday 4th February 2026
Underpinning the Value of Urine for Predictive & Monitoring Biomarkers in Bladder Cancer
5:40 pm
- Comparing utDNA with traditional ctDNA for monitoring disease burden and detecting recurrence
- Optimizing assay sensitivity, specificity & turnaround time for real-world clinical use
- Leveraging longitudinal utDNA analysis to guide treatment decisions and improve patient outcomes
